Mohamedtaki Abdulaziz Tejani

机构：AdventHealth Orlando, Florida Hospital Cancer Institute, Cancer Institute of Florida

发表论文 124 篇 · 总被引 3177 次 · h-index 27

代表论文

• Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma (2024 · The Oncologist · 被引 40)
• DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish (2024 · Journal of Clinical Oncology · 被引 32)
• Zanidatamab in previously-treated HER2-positive (HER2+) biliary tract cancer (BTC): Overall survival (OS) and longer follow-up from the phase 2b HERIZON-BTC-01 study. (2024 · Journal of Clinical Oncology · 被引 21)
• DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B (2025 · Nature Communications · 被引 8)
• Efficacy and safety of olomorasib, a second-generation KRAS G12C inhibitor, plus cetuximab in KRAS G12C-mutant advanced colorectal cancer. (2025 · Journal of Clinical Oncology · 被引 8)
• Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer (2025 · JAMA Oncology · 被引 7)